The company’s EBITDA stood at Rs9cr as compared to Rs14.78cr during the corresponding period of the previous year. EBITDA Margin at 22.8% for Q4FY21 as against 35.8% in Q4FY20.
Net Profit stood at Rs6.47cr for Q4FY21 as compared to Rs10.43cr in the corresponding period of the previous year. Basic EPS stood at Rs4.85 as against Rs7.82 in the corresponding quarter of last fiscal.
During FY21, Total Operating income was Rs143.73cr for FY21 as compared to Rs161.25cr in the corresponding period of the previous year. EBITDA stood at Rs41.19cr as compared to Rs55.73cr during the corresponding period of previous year. EBITDA Margin at 28.7% for FY21 as against 34.6% in FY20.
Net profit stood at Rs28.98cr for FY21 as compared to Rs39.84cr in the corresponding period of the previous year. Basic EPS stood at Rs21.73 as against Rs29.87 in FY20.
The board of directors of the company declared dividend of Rs3.50 as final dividend for the financial year ended March 31, 2021 in addition to an interim dividend of ₹1/-per equity share which was approved in the month of November, 2020.
“We are pleased to report healthy performance during the year despite challenging external environment due to Covid 19 Pandemic throughout the year. These results reflect the reduced demand for Female Condoms specially from South Africa during the quarter and the year as a result of negative impact of this pandemic. The demand for Male and Female Condoms especially in the export market continue to remain strong and our order book continues to be healthy. The order book as on April 1, 2021 stands at Rs113cr,” Omprakash Garg, CMD, said.